FDA approves J & J ’s Tremfya self-injection pen for psoriasis

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis.
The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients.
Get the full story on our sister site, Drug Delivery Business.
The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice.

Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Drug-Device Combinations Food & Drug Administration (FDA) News Well AbbVie Janssen Pharmaceuticals johnsonandjohnson Source Type: news